Anavex Life Sciences Corp. Aktie News

Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...

ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144

Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine”

Anavex Life Sciences Corp. reported positive phase 2 results for ANAVEX 3-71 in schizophrenia, showing improved biomarkers and strong safety. AVXL's ANAVEX 3-71 targets all three schizophrenia domains—positive, negative, and cognitive symptoms—offering a holistic, competitive oral therapy. The company maintains a solid cash position, supporting operations for at least three years, with flexible...

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults

ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treat...

Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer's Disease Patients” Significant improvement in self-assessed Quality of Life (QoL-AD) scores indicating a reversal of negative trajectory for Alzheimer's disease clinical trial participants was obser...

New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer's disease